Moreover, the in vitro impact of targeting constitutively activated ALK in the context of a variant 3 of the EML4 - ALK gene fusion was more pronounced with lorlatinib (highly significant compared to control and lowest IC 50 value) than for crizotinib (not significant compared to control) or ceritinib (significance and half-maximal inhibitory value inferior to lorlatinib; not significant compared to control in JVE404, but significant in NCI-H2228).
1
—
—